South Korea study maps referral patterns in hyperthyroid cats

Version 2

A newly published study in Frontiers in Veterinary Science provides the first detailed look at hyperthyroid cats presented for radioactive iodine therapy in South Korea, analyzing 152 cases and identifying a distinctly pet parent-driven referral pattern. Among the headline findings: 59.9% of cats were brought for radioactive iodine therapy at the initiative of pet parents rather than on a veterinarian’s recommendation, and non-veterinary methimazole formulations were used much more often than veterinary-labeled products. Cats receiving those human-licensed or generic formulations had a higher rate of pruritus, according to the authors. (frontiersin.org)

That matters because feline hyperthyroidism management is already a balancing act between definitive treatment, medical stabilization, renal risk assessment, and client logistics. Longstanding guidance from the American Association of Feline Practitioners describes radioactive iodine as the treatment of choice for most cats, while also noting that treatment selection often depends on age, comorbidities, cost, availability, and clinician expertise. More recent AAHA guidance similarly notes that radioactive iodine can be used as an initial treatment for stable cats, but access remains uneven because treatment requires specialized facilities and isolation protocols. (pmc.ncbi.nlm.nih.gov)

In the South Korea cohort, all cats were housed indoors, and the geographic distribution of cases differed from the national distribution of pet cats. No cats in the study came from Jeju-do, a finding the authors reported as significantly different from mainland regions. The paper also found that longer disease duration was associated with markers of more advanced disease, including higher thyroid hormone concentrations, greater scintigraphic activity, more bilateral thyroid involvement, and a higher likelihood of refractory response to antithyroid drugs. Even so, the authors described “early use of definitive therapy despite a relatively late diagnosis,” suggesting that once pet parents reached referral, they were often willing to move to curative treatment. (frontiersin.org)

The methimazole finding may be especially relevant in daily practice. FDA guidance for the U.S. market notes that veterinary-approved feline methimazole products provide cat-specific dosing and safety information, whereas human methimazole products historically have been used extra-label. The FDA also lists skin reactions, including itchy skin and other lesions, among the most commonly reported adverse events. Independent clinical commentary and reference sources likewise describe facial pruritus or excoriations as a recognized, though uncommon, adverse effect that should prompt reconsideration of therapy. (fda.gov)

Industry reaction specific to this paper appears limited so far, but the findings fit with broader expert guidance. AAFP and AAHA resources both emphasize that methimazole is effective and widely used, yet requires ongoing monitoring and dose adjustment because it controls hormone production rather than eliminating the underlying adenomatous tissue. Those same guidelines continue to position radioactive iodine as the preferred definitive option for many cats because it can resolve hyperthyroidism with a single treatment and avoids chronic medication administration. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, this study is less about changing the standard of care than about exposing how care is actually being delivered in one market. It shows how pet parent research and initiative may drive referral decisions, how product availability can push clinics toward extra-label prescribing, and how treatment delays may coincide with more advanced disease by the time cats reach radioactive iodine centers. It also reinforces a practical point familiar to internists: if a cat develops methimazole-associated pruritus, clinicians may need to pivot quickly to another strategy, including radioactive iodine, surgery, or diet, depending on the case. (frontiersin.org)

For practices outside South Korea, the paper still has value as a comparative benchmark. It adds to the limited published literature on feline radioactive iodine therapy in Korea, where an earlier small case series described the country’s first investigation of locally manufactured radioiodine treatment in 10 hyperthyroid cats. Together, the reports suggest the referral ecosystem and treatment infrastructure for feline hyperthyroidism may be evolving, with case selection and client demand shaping how quickly definitive care is adopted. (kjvr.org)

What to watch: The next step will be whether larger follow-up studies connect these referral and prescribing patterns to long-term outcomes, including cure rates, hypothyroidism risk, renal unmasking, and adverse-event rates, and whether they influence clinician education or access to veterinary-labeled antithyroid drugs in South Korea. (aaha.org)